These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 38558124)

  • 1. Management of Pulmonary Hypertension in the Context of Heart Failure with Preserved Ejection Fraction.
    Kozaily E; Akdogan ER; Dorsey NS; Tedford RJ
    Curr Hypertens Rep; 2024 Jul; 26(7):291-306. PubMed ID: 38558124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.
    Lai YC; Wang L; Gladwin MT
    J Physiol; 2019 Feb; 597(4):1143-1156. PubMed ID: 30549058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary hypertension in heart failure with preserved ejection fraction.
    Guazzi M; Gomberg-Maitland M; Arena R
    J Heart Lung Transplant; 2015 Mar; 34(3):273-81. PubMed ID: 25577563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Heart Failure with Preserved Ejection Fraction.
    Ilieșiu AM; Hodorogea AS
    Adv Exp Med Biol; 2018; 1067():67-87. PubMed ID: 29498023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction.
    Obokata M; Kane GC; Reddy YNV; Melenovsky V; Olson TP; Jarolim P; Borlaug BA
    Eur Heart J; 2019 Dec; 40(45):3707-3717. PubMed ID: 31513270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials.
    Meifang W; Ying W; Wen C; Kaizu X; Meiyan S; Liming L
    Heart Fail Rev; 2024 Mar; 29(2):305-320. PubMed ID: 37561223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
    Kramer T; Dumitrescu D; Gerhardt F; Orlova K; Ten Freyhaus H; Hellmich M; Baldus S; Rosenkranz S
    Int J Cardiol; 2019 May; 283():152-158. PubMed ID: 30777406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension.
    Patel RB; Li E; Benefield BC; Swat SA; Polsinelli VB; Carr JC; Shah SJ; Markl M; Collins JD; Freed BH
    ESC Heart Fail; 2020 Feb; 7(1):253-263. PubMed ID: 31903694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary hypertension secondary to heart failure with preserved ejection fraction.
    Thenappan T; Prins KW; Cogswell R; Shah SJ
    Can J Cardiol; 2015 Apr; 31(4):430-9. PubMed ID: 25840094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Right Ventricular and Right Atrial Function Are Less Compromised in Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction: A Comparison With Pulmonary Arterial Hypertension With Similar Pressure Overload.
    van Wezenbeek J; Kianzad A; van de Bovenkamp A; Wessels J; Mouratoglou SA; Braams NJ; Jansen SMA; Meulblok E; Meijboom LJ; Marcus JT; Vonk Noordegraaf A; José Goumans M; Jan Bogaard H; Handoko ML; de Man FS
    Circ Heart Fail; 2022 Feb; 15(2):e008726. PubMed ID: 34937392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction.
    Andersen MJ; Hwang SJ; Kane GC; Melenovsky V; Olson TP; Fetterly K; Borlaug BA
    Circ Heart Fail; 2015 May; 8(3):542-50. PubMed ID: 25857307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review.
    Hiraiwa H; Okumura T; Murohara T
    Am J Cardiovasc Drugs; 2024 May; 24(3):343-369. PubMed ID: 38575813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction.
    Vanderpool RR; Saul M; Nouraie M; Gladwin MT; Simon MA
    JAMA Cardiol; 2018 Apr; 3(4):298-306. PubMed ID: 29541759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction.
    Wang L; Halliday G; Huot JR; Satoh T; Baust JJ; Fisher A; Cook T; Hu J; Avolio T; Goncharov DA; Bai Y; Vanderpool RR; Considine RV; Bonetto A; Tan J; Bachman TN; Sebastiani A; McTiernan CF; Mora AL; Machado RF; Goncharova EA; Gladwin MT; Lai YC
    Arterioscler Thromb Vasc Biol; 2020 Jun; 40(6):1543-1558. PubMed ID: 32268788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of pharmacologic interventions--treating endothelial dysfunction and group 2 pulmonary hypertension.
    Guazzi M; Gomberg-Maitland M; Naeije R
    Prog Cardiovasc Dis; 2015; 57(5):473-9. PubMed ID: 25446553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group 2 PH: Medical Therapy.
    Guazzi M; Labate V
    Prog Cardiovasc Dis; 2016; 59(1):71-7. PubMed ID: 27389809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of left ventricular diastolic function profile in patients with pulmonary hypertension due to heart failure with preserved ejection fraction.
    Raeisi-Giglou P; Lam L; Tamarappoo BK; Newman J; Dweik RA; Tonelli AR
    Clin Cardiol; 2017 Jun; 40(6):356-363. PubMed ID: 28026030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
    Guazzi M; Vicenzi M; Arena R; Guazzi MD
    Circulation; 2011 Jul; 124(2):164-74. PubMed ID: 21709061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Mouse Model of Metabolic Syndrome, Pulmonary Hypertension, and Heart Failure with Preserved Ejection Fraction.
    Meng Q; Lai YC; Kelly NJ; Bueno M; Baust JJ; Bachman TN; Goncharov D; Vanderpool RR; Radder JE; Hu J; Goncharova E; Morris AM; Mora AL; Shapiro SD; Gladwin MT
    Am J Respir Cell Mol Biol; 2017 Apr; 56(4):497-505. PubMed ID: 28118022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.